These included the “Metabolic pathways,” “EGFR tyrosine kinase inhibitor resistance,” “Non-small cell lung cancer,” “PI3K-Akt signaling,” and “B cell receptor signaling” pathways (Figure 3C). This evidence concerns the gene PIK3CD and non-small cell lung carcinoma.